Reaching a target weight does not automatically end treatment or daily care. Discuss continuation or stopping with your clinician, and use food, activity and weight records to review a maintenance plan.
What did the STEP 1 extension show?
The 2022 STEP 1 extension reported that participants regained, on average, about two-thirds of their previous weight loss during the year after semaglutide 2.4 mg and structured lifestyle intervention were stopped.[1]
This is a group average, not an inevitable individual outcome or a 67% increase in body weight. Both medication and structured lifestyle intervention ended, so it cannot be reduced to the effect of medication withdrawal alone. It does not directly predict outcomes for other products, doses or care settings.
Plan maintenance before deciding when to stop
NIDDK explains that weight may return after weight-management medication is stopped and that lasting nutrition and activity habits matter.[2] Discuss treatment duration with your clinician in light of effectiveness, adverse effects and health.
Ask about follow-up visits, health measures to track and what to do if weight changes after your goal. Using an app is not a reason to independently reduce, stop or restart medication.
Records to review in maintenance
- Weights measured in comparable conditions, with dates.
- Missed meals or days with unusual appetite.
- Actual activity time and strength-training records.
- Changes and questions to discuss at your next visit.
Records are for understanding, not judging yourself
When a number changes, consider circumstances and how you feel. Resume with the next entry rather than inventing missing data. GLP1 Helper can organize these observations by date; it does not guarantee prevention of weight regain.
A small check-in today
- Have you planned follow-up beyond your initial goal?
- Have you chosen what to monitor in maintenance?
- Have you discussed medication changes with your clinician?
Frequently asked questions
Can I stop as soon as I reach my target weight?
Do not decide independently. Discuss continuation, stopping or changes with your prescriber based on response, adverse effects and health.
The GLP1 Helper editorial team prepared this general information from public sources. It has not received individual medical-expert review. It does not replace diagnosis or prescribing. Confirm approved uses and instructions in your country with your prescriber or pharmacist. Editorial principles
References
- Wilding et al. · Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (2022)Clinical-trial extension · DOI 10.1111/dom.14725 · Source checked 2026-10-02
- NIDDK · Prescription Medications to Treat Overweight & ObesityUS public agency · patient information · Source checked 2026-10-02